Risk Factors for Delta Hepatitis in a North American Cohort: Who Should Be Screened?
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 33027083.
- Also identified by DOI 10.14309/ajg.0000000000000954 and PMC identifier 9205618.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The American Association for the Study of Liver Diseases recommends hepatitis D virus (HDV) screening in certain high-risk groups; however, the effectiveness is unknown. A study of North American patients with hepatitis B (HBV) referred to the NIH was performed to identify risk factors associated with HDV infection. Active HDV was "confirmed" by serum HDV RNA or histologic HDV antigen staining. Six hundred fifty-two were studied, of which 91 were HDV "confirmed." Independent risk factors for HDV included: intravenous drug users, HBV-DNA <2,000 IU/mL, alanine aminotransferase >40 U/L, and HDV endemic country of origin. North American patients with HBV and significant risk factors should be screened for HDV.
Medical subject headings
- Adult
- Alanine Transaminase/blood
- Alkaline Phosphatase/blood
- Aspartate Aminotransferases/blood
- Cohort Studies
- Coinfection
- DNA, Viral/blood
- Emigrants and Immigrants
- Endemic Diseases
- Female
- Hepatitis Antibodies/blood
- Hepatitis B, Chronic/blood
- Hepatitis B, Chronic/epidemiology
- Hepatitis D/blood
- Hepatitis D/diagnosis
- Hepatitis D/epidemiology
- Hepatitis delta Antigens/blood
- Humans
- Male
- Mass Screening
- Middle Aged
- Platelet Count
- Prothrombin Time
- RNA, Viral/blood
- Retrospective Studies
- Risk Assessment
- Risk Factors
- Serum Albumin/metabolism
- Substance Abuse, Intravenous/epidemiology
- United States/epidemiology
- Viral Load
- gamma-Glutamyltransferase/blood